Sunday, October 08, 2017

Advocates In California Urge Protection For Medical Cannabis Patients From Hyper-regulation, Over-taxation, & Corporate Takeover

The Bureau of Cannabis Control is slated to start issuing and processing applications on January 1, 2018.  Further regulations will be presented in November of this year, and the California Department of Consumer Affairs just seated the long-waited Cannabis Advisory Committee mandated by the state’s new cannabis rules.  

What is absent on this committee is any authentic patient voice or social justice advocates.  However, this has been the case in Sacramento during all medical cannabis policy discussions.  Patient advocates have had to demand to be heard or be ignored.  Now that the potential revenue from adult recreational cannabis sales and production is being projected, affordable access to medical cannabis for disabled and low-income patients is the furthest thing on the minds of the new Cannabis Bureaucracy.

Hopefully, the California Cannabis Bureaucracy realizes that we could find ourselves back in a federally hostile environment.  Who did they seat to tackle the possibility that our U.S. Attorney General and Department of Justice may decide to enforce the Controlled Substances Act, again?  Who will deal with the fallout and stand up for the political prisoners?

What is present on this committee is the Drug Policy Alliance.  Members of the Drug Policy Alliance are gaining seats on committees and commissions around the state.  Since DPA’s political action committee donated a significant amount of money to Prop. 64, this would seem to be a conflict.  However, this works out wonderfully for George Soros, who founded and funds DPA, and is heavily vested in Monsanto.   Monsanto stands to win the most from Prop. 64, by acquiring the largest permits and controlling the seeds for recreational, medical and hemp stains.  With Soros’ employees serving around the state the mega-corporate take over of California’s cannabis industry is moving right along.

Despite how the advisory or oversight bodies may be stacked, the regulations themselves equate impractical policy.  Many current businesses will find it burdensome and too expensive to comply.  This creates a monopoly for wealthy, elite players to saturate the marketplace.  True patients and their providers will be priced out and in jeopardy.  Some operations will go deep underground, adding to existing environmental concerns about unregulated cultivation.

Patients are urged to contact:

Department of Consumer Affairs – Bureau of Cannabis Control

Attn: Lori Ajax, Chief, Bureau of Cannabis Control;
Dean R. Grafilo, Director, California Department of Consumer Affairs;
And Members of the Cannabis Advisory Committee

Or (800) 952-5210

Let them know that you are patient that relies on consistent and affordable access to medical cannabis, and you are concerned that over-regulation, permitting fees and taxes for medical cannabis are going to put your collective out of business or make it so you can no longer afford your medicine. 

Send your comments and concerns to your California state representatives as well:
Find Your California Representative


Some related links:
Department of Consumer Affairs Announces Appointments to Cannabis Advisory Committee

L.A. City Council approves new Cannabis Department head

George Soros And Big Agriculture Move The Marijuana Movement

How Monsanto & Bayer Are Trying To Take Over The Cannabis Industry

The Corporate Billionaires’ Hostile Attempt To Take Over The California Cannabis Industry in 2016

Legalization, 4 Years Later: What Happened In Washington State?